Humacyte Inc (HUMA)

$3.54 -0.21 (-5.60%)
Market Cap 471.97M
Revenue (ttm) 0.00
Net Income (ttm) -110.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,627,900
Avg Vol 4,414,680
Day's Range N/A - N/A
Shares Out 125.86M
Stochastic %K 0%
Beta 1.30
Analysts Strong Sell
Price Target $13.14

Latest News on HUMA

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 2 days ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 4 weeks ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 5 weeks ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Jan 9, 2025, 5:45 AM EST - 6 weeks ago

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 2, 2025, 8:15 AM EST - 7 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm

Dec 21, 2024, 12:15 PM EST - 2 months ago

Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm

Humacyte stock may fail to sustain today's gains: find out more

Dec 20, 2024, 12:35 PM EST - 2 months ago

Humacyte stock may fail to sustain today's gains: find out more

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman

Dec 20, 2024, 10:30 AM EST - 2 months ago

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

Dec 20, 2024, 8:15 AM EST - 2 months ago

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Dec 19, 2024, 10:47 PM EST - 2 months ago

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Humacyte, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 19, 2024, 1:30 PM EST - 2 months ago

Humacyte, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman

Dec 19, 2024, 1:24 PM EST - 2 months ago

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit – HUMA

Dec 18, 2024, 1:34 PM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit – HUMA

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Dec 18, 2024, 10:04 AM EST - 2 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman

Dec 16, 2024, 3:36 PM EST - 2 months ago

Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman